BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rosenfeld M, Wainwright CE, Higgins M, Wang LT, McKee C, Campbell D, Tian S, Schneider J, Cunningham S, Davies JC; ARRIVAL study group. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet Respir Med 2018;6:545-53. [PMID: 29886024 DOI: 10.1016/S2213-2600(18)30202-9] [Cited by in Crossref: 102] [Cited by in F6Publishing: 31] [Article Influence: 25.5] [Reference Citation Analysis]
Number Citing Articles
1 Slae M, Wilschanski M. Cystic fibrosis and the gut. Frontline Gastroenterol 2021;12:622-8. [PMID: 34917319 DOI: 10.1136/flgastro-2020-101610] [Reference Citation Analysis]
2 Chen J, Ahmed MU, Zhu C, Yu S, Pan W, Velkov T, Li J, Tony Zhou Q. In vitro evaluation of drug delivery behavior for inhalable amorphous nanoparticle formulations in a human lung epithelial cell model. Int J Pharm 2021;596:120211. [PMID: 33486036 DOI: 10.1016/j.ijpharm.2021.120211] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Freswick PN, Reid EK, Mascarenhas MR. Pancreatic Enzyme Replacement Therapy in Cystic Fibrosis. Nutrients 2022;14:1341. [PMID: 35405954 DOI: 10.3390/nu14071341] [Reference Citation Analysis]
4 Regard L, Martin C, Burnet E, Da Silva J, Burgel P. CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France. Cells 2022;11:1769. [DOI: 10.3390/cells11111769] [Reference Citation Analysis]
5 Clancy JP. Rapid therapeutic advances in CFTR modulator science. Pediatr Pulmonol 2018;53:S4-S11. [PMID: 30289627 DOI: 10.1002/ppul.24157] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
6 Mainz JG, Zagoya C, Polte L, Naehrlich L, Sasse L, Eickmeier O, Smaczny C, Barucha A, Bechinger L, Duckstein F, Kurzidim L, Eschenhagen P, Caley L, Peckham D, Schwarz C. Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score. Front Pharmacol 2022;13:877118. [PMID: 35721187 DOI: 10.3389/fphar.2022.877118] [Reference Citation Analysis]
7 Aurora P, Duncan JA, Lum S, Davies G, Wade A, Stocks J, Viviani L, Raywood E, Pao C, Ruiz G, Bush A. Early Pseudomonas aeruginosa predicts poorer pulmonary function in preschool children with cystic fibrosis. Journal of Cystic Fibrosis 2022. [DOI: 10.1016/j.jcf.2022.04.013] [Reference Citation Analysis]
8 Li Q, Liu S, Ma X, Yu J. Effectiveness and Safety of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Children With Cystic Fibrosis: A Meta-Analysis. Front Pediatr 2022;10:937250. [DOI: 10.3389/fped.2022.937250] [Reference Citation Analysis]
9 Hubert D, Marguet C, Benichou J, DeSouza C, Payen-Champenois C, Kinnman N, Chandarana K, Munck A, Fajac I; BRIO Study Group. Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization. Pulm Ther 2021. [PMID: 34101145 DOI: 10.1007/s41030-021-00158-5] [Reference Citation Analysis]
10 McGlynn JA, Langfelder-Schwind E. Bridging the Gap between Scientific Advancement and Real-World Application: Pediatric Genetic Counseling for Common Syndromes and Single-Gene Disorders. Cold Spring Harb Perspect Med 2020;10:a036640. [PMID: 31570386 DOI: 10.1101/cshperspect.a036640] [Reference Citation Analysis]
11 Rosenfeld M, Cunningham S, Harris WT, Lapey A, Regelmann WE, Sawicki GS, Southern KW, Chilvers M, Higgins M, Tian S, Cooke J, Davies JC; KLIMB study group. An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB). J Cyst Fibros 2019;18:838-43. [PMID: 31053538 DOI: 10.1016/j.jcf.2019.03.009] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 12.7] [Reference Citation Analysis]
12 van Koningsbruggen-Rietschel S. Getting Near to "Closing the Gap" in the Pediatric Age Group for the First Personalized Treatment of Cystic Fibrosis. Am J Respir Crit Care Med 2021;203:536-7. [PMID: 33113333 DOI: 10.1164/rccm.202010-3848ED] [Reference Citation Analysis]
13 Bass R, Brownell JN, Stallings VA. The Impact of Highly Effective CFTR Modulators on Growth and Nutrition Status. Nutrients 2021;13:2907. [PMID: 34578785 DOI: 10.3390/nu13092907] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Petrocheilou A, Kaditis AG, Loukou I. Pancreatitis in A Patient with Cystic Fibrosis Taking Ivacaftor. Children (Basel) 2020;7:E6. [PMID: 31940891 DOI: 10.3390/children7010006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Coverstone AM, Ferkol TW. Early Diagnosis and Intervention in Cystic Fibrosis: Imagining the Unimaginable. Front Pediatr 2020;8:608821. [PMID: 33505947 DOI: 10.3389/fped.2020.608821] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Meoli A, Fainardi V, Deolmi M, Chiopris G, Marinelli F, Caminiti C, Esposito S, Pisi G. State of the Art on Approved Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators and Triple-Combination Therapy. Pharmaceuticals (Basel) 2021;14:928. [PMID: 34577628 DOI: 10.3390/ph14090928] [Reference Citation Analysis]
17 Caird R, Williamson M, Yusuf A, Gogoi D, Casey M, McElvaney NG, Reeves EP. Targeting of Glycosaminoglycans in Genetic and Inflammatory Airway Disease. Int J Mol Sci 2022;23:6400. [PMID: 35742845 DOI: 10.3390/ijms23126400] [Reference Citation Analysis]
18 Andrade A, Pizarro ME. Medicina de precisión en fibrosis quística. Revista Médica Clínica Las Condes 2022;33:44-50. [DOI: 10.1016/j.rmclc.2021.12.003] [Reference Citation Analysis]
19 Naehrlich L. The Changing Face of Cystic Fibrosis and Its Implications for Screening. Int J Neonatal Screen 2020;6:54. [PMID: 33123635 DOI: 10.3390/ijns6030054] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
20 Aalbers B, de Winter-de Groot K, Arets H, Hofland R, de Kiviet A, van Oirschot-van de Ven M, Kruijswijk M, Schotman S, Michel S, van der Ent C, Heijerman H. Clinical effect of lumacaftor/ivacaftor in F508del homozygous CF patients with FEV1 ≥ 90% predicted at baseline. Journal of Cystic Fibrosis 2020;19:654-8. [DOI: 10.1016/j.jcf.2019.12.015] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
21 Roda J, Pinto-silva C, Silva IA, Maia C, Almeida S, Ferreira R, Oliveira G. New drugs in cystic fibrosis: what has changed in the last decade? Therapeutic Advances in Chronic Disease 2022;13:204062232210981. [DOI: 10.1177/20406223221098136] [Reference Citation Analysis]
22 Clunes LA, McMillan-Castanares N, Mehta N, Mesadieu A, Rodriguez J, Maj M, Clunes MT. Epithelial vectorial ion transport in cystic fibrosis: Dysfunction, measurement, and pharmacotherapy to target the primary deficit. SAGE Open Med 2020;8:2050312120933807. [PMID: 32637102 DOI: 10.1177/2050312120933807] [Reference Citation Analysis]
23 McBennett K, MacAskill CJ, Keshock E, Mahani MG, Mata J, Towbin AJ, Sankararaman S, Drumm ML, Yu X, Ren CL, Nasr SZ, Kutney K, Flask CA. Magnetic resonance imaging of cystic fibrosis: Multi-organ imaging in the age of CFTR modulator therapies. J Cyst Fibros 2021:S1569-1993(21)02143-3. [PMID: 34879996 DOI: 10.1016/j.jcf.2021.11.006] [Reference Citation Analysis]
24 Duckers J, Lesher B, Thorat T, Lucas E, McGarry LJ, Chandarana K, De Iorio F. Real-World Outcomes of Ivacaftor Treatment in People with Cystic Fibrosis: A Systematic Review. J Clin Med 2021;10:1527. [PMID: 33917386 DOI: 10.3390/jcm10071527] [Reference Citation Analysis]
25 Sanders DB, Nichols DP. Developmental Milestones in Pediatric Research: A Case for Including Efficacy as Part of Interventional Trials in Infants with Cystic Fibrosis. Am J Respir Crit Care Med 2019;199:1181-2. [PMID: 30422678 DOI: 10.1164/rccm.201811-2103ED] [Reference Citation Analysis]
26 McBennett KA, Davis PB, Konstan MW. Increasing life expectancy in cystic fibrosis: Advances and challenges. Pediatr Pulmonol 2021. [PMID: 34672432 DOI: 10.1002/ppul.25733] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Petersen MC, Begnel L, Wallendorf M, Litvin M. Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis. J Cyst Fibros 2021:S1569-1993(21)02153-6. [PMID: 34862121 DOI: 10.1016/j.jcf.2021.11.012] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
28 King JA, Nichols A, Bentley S, Carr SB, Davies JC. An Update on CFTR Modulators as New Therapies for Cystic Fibrosis. Pediatr Drugs. [DOI: 10.1007/s40272-022-00509-y] [Reference Citation Analysis]
29 Balfour-Lynn IM, King JA. CFTR modulator therapies - Effect on life expectancy in people with cystic fibrosis. Paediatr Respir Rev 2020:S1526-0542(20)30081-6. [PMID: 32565113 DOI: 10.1016/j.prrv.2020.05.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
30 McGarry ME, McColley SA. Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype. Pediatr Pulmonol 2021;56:1496-503. [PMID: 33470563 DOI: 10.1002/ppul.25285] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
31 Fidler MC, Buckley A, Sullivan JC, Statia M, Boj SF, Vries RGJ, Munck A, Higgins M, Moretto Zita M, Negulescu P, van Goor F, De Boeck K. G970R-CFTR Mutation (c.2908G>C) Results Predominantly in a Splicing Defect. Clin Transl Sci 2021;14:656-63. [PMID: 33278322 DOI: 10.1111/cts.12927] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
32 Bratcher PE, Yadav S, Shaughnessy CA, Thornell IM, Zeitlin PL. Effect of apical chloride concentration on the measurement of responses to CFTR modulation in airway epithelia cultured from nasal brushings. Physiol Rep 2020;8:e14603. [PMID: 33038073 DOI: 10.14814/phy2.14603] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
33 Bardin P, Sonneville F, Corvol H, Tabary O. Emerging microRNA Therapeutic Approaches for Cystic Fibrosis. Front Pharmacol 2018;9:1113. [PMID: 30349480 DOI: 10.3389/fphar.2018.01113] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
34 Shei RJ, Mackintosh KA, Peabody Lever JE, McNarry MA, Krick S. Exercise Physiology Across the Lifespan in Cystic Fibrosis. Front Physiol 2019;10:1382. [PMID: 31780953 DOI: 10.3389/fphys.2019.01382] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Stahl M, Steinke E, Mall MA. Quantification of Phenotypic Variability of Lung Disease in Children with Cystic Fibrosis. Genes (Basel) 2021;12:803. [PMID: 34070354 DOI: 10.3390/genes12060803] [Reference Citation Analysis]
36 Tosco A, Villella VR, Raia V, Kroemer G, Maiuri L. Cystic Fibrosis: New Insights into Therapeutic Approaches. CRMR 2020;15:174-86. [DOI: 10.2174/1573398x15666190702151613] [Reference Citation Analysis]
37 Thorat T, McGarry LJ, Jariwala-Parikh K, Limone B, Bonafede M, Chandarana K, Konstan MW. Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States. Pulm Ther 2021;7:281-93. [PMID: 33913076 DOI: 10.1007/s41030-021-00154-9] [Reference Citation Analysis]
38 Pilewski JM, De Boeck K, Nick JA, Tian S, DeSouza C, Higgins M, Moss RB. Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations. Pulm Ther 2020;6:303-13. [PMID: 32965659 DOI: 10.1007/s41030-020-00129-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
39 De Boeck K. Cystic fibrosis in the year 2020: A disease with a new face. Acta Paediatr 2020;109:893-9. [PMID: 31899933 DOI: 10.1111/apa.15155] [Cited by in Crossref: 71] [Cited by in F6Publishing: 48] [Article Influence: 35.5] [Reference Citation Analysis]
40 Gabel ME, Fox CK, Grimes RA, Lowman JD, McDonald CM, Stallings VA, Michel SH. Overweight and cystic fibrosis: An unexpected challenge. Pediatr Pulmonol 2021. [PMID: 34738328 DOI: 10.1002/ppul.25748] [Reference Citation Analysis]
41 Ronan NJ, Einarsson GG, Deane J, Fouhy F, Rea M, Hill C, Shanahan F, Elborn JS, Ross RP, McCarthy M, Murphy DM, Eustace JA, Mm T, Stanton C, Plant BJ. Modulation, microbiota and inflammation in the adult CF gut: A prospective study. J Cyst Fibros 2022:S1569-1993(22)00589-6. [PMID: 35764510 DOI: 10.1016/j.jcf.2022.06.002] [Reference Citation Analysis]
42 Sergeev V, Chou FY, Lam GY, Hamilton CM, Wilcox PG, Quon BS. The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis. Ann Am Thorac Soc 2020;17:147-54. [PMID: 31661636 DOI: 10.1513/AnnalsATS.201909-671CME] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 24.0] [Reference Citation Analysis]
43 Despotes KA, Donaldson SH. Current state of CFTR modulators for treatment of Cystic Fibrosis. Current Opinion in Pharmacology 2022;65:102239. [DOI: 10.1016/j.coph.2022.102239] [Reference Citation Analysis]
44 Caudri D, Turkovic L, de Klerk NH, Rosenow T, Murray CP, Steyerberg EW, Ranganathan SC, Sly P, Stick SM, Breuer O; AREST CF Study Group. A screening tool to identify risk for bronchiectasis progression in children with cystic fibrosis. Pediatr Pulmonol 2022;57:122-31. [PMID: 34596357 DOI: 10.1002/ppul.25712] [Reference Citation Analysis]
45 Dobra R, Edmondson C, Hughes D, Martin I, Davies JC. Potentiators and Correctors in Paediatric Cystic Fibrosis Patients: A Narrative Review. Paediatr Drugs 2018;20:555-66. [PMID: 30328089 DOI: 10.1007/s40272-018-0315-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
46 Coulthard KP. Cystic fibrosis: novel therapies, remaining challenges. J Pharm Pract Res 2018;48:569-77. [DOI: 10.1002/jppr.1516] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
47 Davies JC, Wainwright CE, Sawicki GS, Higgins MN, Campbell D, Harris C, Panorchan P, Haseltine E, Tian S, Rosenfeld M. Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial. Am J Respir Crit Care Med 2021;203:585-93. [PMID: 33023304 DOI: 10.1164/rccm.202008-3177OC] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 11.0] [Reference Citation Analysis]
48 Lahiri T, Sullivan JS. Recent advances in the early treatment of cystic fibrosis: Bridging the gap to highly effective modulator therapy. Pediatr Pulmonol 2021. [PMID: 34473419 DOI: 10.1002/ppul.25660] [Reference Citation Analysis]
49 Lopes-Pacheco M. CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine. Front Pharmacol 2019;10:1662. [PMID: 32153386 DOI: 10.3389/fphar.2019.01662] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 31.5] [Reference Citation Analysis]
50 Bradbury NA. Cystic Fibrosis and Genotype-Dependent Therapy: Is There a Need for a Sex-Specific Therapy? Gender and the Genome 2020;4:247028972093702. [DOI: 10.1177/2470289720937025] [Reference Citation Analysis]
51 Girón Moreno RM, García-Clemente M, Diab-Cáceres L, Martínez-Vergara A, Martínez-García MÁ, Gómez-Punter RM. Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review. Antibiotics (Basel) 2021;10:486. [PMID: 33922413 DOI: 10.3390/antibiotics10050486] [Reference Citation Analysis]
52 Fuchs T, Appelt D, Niedermayr K, Ellemunter H. REAL-world clinical effectiveness of ivacaftor therapy in the first 24 months in two infants with cystic fibrosis and different gating mutations-A case report. Clin Case Rep 2022;10:e05364. [PMID: 35154718 DOI: 10.1002/ccr3.5364] [Reference Citation Analysis]
53 Habib AR, Kajbafzadeh M, Desai S, Yang CL, Skolnik K, Quon BS. A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis. Sci Rep 2019;9:7234. [PMID: 31076617 DOI: 10.1038/s41598-019-43652-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
54 Hoppe JE, Wagner BD, Kirk Harris J, Rowe SM, Heltshe SL, Deboer EM, Sagel SD. Effects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551D. Journal of Cystic Fibrosis 2022. [DOI: 10.1016/j.jcf.2022.03.012] [Reference Citation Analysis]
55 Ray TR, Ivanovic M, Curtis PM, Franklin D, Guventurk K, Jeang WJ, Chafetz J, Gaertner H, Young G, Rebollo S, Model JB, Lee SP, Ciraldo J, Reeder JT, Hourlier-Fargette A, Bandodkar AJ, Choi J, Aranyosi AJ, Ghaffari R, McColley SA, Haymond S, Rogers JA. Soft, skin-interfaced sweat stickers for cystic fibrosis diagnosis and management. Sci Transl Med 2021;13:eabd8109. [PMID: 33790027 DOI: 10.1126/scitranslmed.abd8109] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
56 Taylor-Cousar JL, Mall MA, Ramsey BW, McKone EF, Tullis E, Marigowda G, McKee CM, Waltz D, Moskowitz SM, Savage J, Xuan F, Rowe SM. Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles. ERJ Open Res 2019;5:00082-2019. [PMID: 31218221 DOI: 10.1183/23120541.00082-2019] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 10.7] [Reference Citation Analysis]
57 Mckay IR, Ooi CY. The Exocrine Pancreas in Cystic Fibrosis in the Era of CFTR Modulation: A Mini Review. Front Pediatr 2022;10:914790. [DOI: 10.3389/fped.2022.914790] [Reference Citation Analysis]
58 Farrell PM, Rock MJ, Baker MW. The Impact of the CFTR Gene Discovery on Cystic Fibrosis Diagnosis, Counseling, and Preventive Therapy. Genes (Basel) 2020;11:E401. [PMID: 32276344 DOI: 10.3390/genes11040401] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
59 Simmonds NJ, van der Ent CK, Colombo C, Kinnman N, Desouza C, Thorat T, Chew ML, Chandarana K, Castellani C. VOCAL: An observational study of ivacaftor for people with cystic fibrosis and selected non–G551D-CFTR gating mutations. Journal of Cystic Fibrosis 2022. [DOI: 10.1016/j.jcf.2022.05.007] [Reference Citation Analysis]
60 Wright BA, Cannon ME, Ramsey LJ. Reversing the irreversible: Another potential benefit of CFTR modulators. Pediatr Pulmonol 2020;55:2844-5. [PMID: 32876397 DOI: 10.1002/ppul.25047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
61 Costa E, Girotti S, Pauro F, Leufkens HGM, Cipolli M. The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis. Orphanet J Rare Dis 2022;17:188. [PMID: 35525974 DOI: 10.1186/s13023-022-02350-5] [Reference Citation Analysis]
62 Szentpetery S, Foil K, Hendrix S, Gray S, Mingora C, Head B, Johnson D, Flume PA. A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus. Journal of Cystic Fibrosis 2022. [DOI: 10.1016/j.jcf.2022.04.005] [Reference Citation Analysis]
63 Skilton M, Krishan A, Patel S, Sinha IP, Southern KW. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. Cochrane Database Syst Rev 2019;1:CD009841. [PMID: 30616300 DOI: 10.1002/14651858.CD009841.pub3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
64 Barry PJ, Taylor-Cousar JL. Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world - opportunities and challenges. Curr Opin Pulm Med 2021;27:554-66. [PMID: 34420018 DOI: 10.1097/MCP.0000000000000819] [Reference Citation Analysis]
65 Fajac I, Sermet-Gaudelus I. Emerging medicines to improve the basic defect in cystic fibrosis. Expert Opin Emerg Drugs 2022. [PMID: 35731915 DOI: 10.1080/14728214.2022.2092612] [Reference Citation Analysis]
66 Johns JD, Rowe SM. The effect of CFTR modulators on a cystic fibrosis patient presenting with recurrent pancreatitis in the absence of respiratory symptoms: a case report. BMC Gastroenterol 2019;19:123. [PMID: 31296159 DOI: 10.1186/s12876-019-1044-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
67 Mayer-Hamblett N, van Koningsbruggen-Rietschel S, Nichols DP, VanDevanter DR, Davies JC, Lee T, Durmowicz AG, Ratjen F, Konstan MW, Pearson K, Bell SC, Clancy JP, Taylor-Cousar JL, De Boeck K, Donaldson SH, Downey DG, Flume PA, Drevinek P, Goss CH, Fajac I, Magaret AS, Quon BS, Singleton SM, VanDalfsen JM, Retsch-Bogart GZ. Building global development strategies for cf therapeutics during a transitional cftr modulator era. J Cyst Fibros 2020;19:677-87. [PMID: 32522463 DOI: 10.1016/j.jcf.2020.05.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]